Pulse Evolution Corporation to Host Investor Conference Call

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pulse Evolution Corporation to Host Investor Conference Call on April 8, 2015

PORT ST. LUCIE, Fla., April 3, 2015 (GLOBE NEWSWIRE) -- via PRWEB - Pulse Evolution Corporation (OTC:PLFX) will conduct its first investor conference call as a publicly listed company, on Wednesday, April 8, 2015 at 11:00am EST, hosted by John Textor, Executive Chairman, who will discuss the following topics:

  • The Pulse Evolution Business Model, including a discussion of the near-term monetization opportunities associated with the Company's pioneering role in the new form of entertainment, known as Virtual Performance, and the ownership and exploitation of 'Digital Likeness Rights'.
  • Review of Start-up and Development Stage Initiatives and Operating Results, a discussion of successes, failures and second stage objectives.
  • Capitalization and Liquidity, including public disclosure of recent Third Fiscal Quarter consummation of $3.97 Million financing and rights participation agreements.
  • Report on Existing Agreements and relationships with the estates of Michael Jackson, Elvis Presley and Marilyn Monroe, including extension and expansion of exclusive relationship with Elvis Presley / Authentic Brands Group.
  • Capitalization, development and production of 'The King', an original, full-length musical, featuring a hyper-real animated performance of the legendary musician Elvis Presley. "The King" is scheduled to open in Q4 of 2016, and then roll out in major cities around the world.
  • Pending Strategic Partnerships and Acquisitions, including the planned acquisition of important enabling animation technologies, the acquisition of holographic display technologies for the mobile market and the expectation of alignments with specific major entertainment and consumer products companies.
  • Business Segment Expansion, including the launch of Pulse Biologic, and International Development and Capital Joint Ventures, including current discussions with potential partners in Singapore and Tokyo.

Conference Call and Web-link Details

The conference call will begin at 11:00 EST and will be broadcast live over the Internet and telephone via the following:

Web conference link: https://meetingvisuals.webex.com/meetingvisua...406e39cb3b

Audio conference information: Participants' toll-free dial-in number (U.S. and Canada):
(855) 803-7434

International dial-in number:
(704) 288-0506

Meeting number: 593 854 105

About Pulse Evolution Corporation

Pulse Evolution Corporation ("Pulse" or "Company") is a next generation technology and intellectual property company, established to produce specialized, high-impact applications of computer-generated human likeness – or "digital human beings" – for utilization in entertainment, life sciences, education and telecommunications.

In its first year of operation, Pulse emerged as the leader in the new, globally relevant digital performance industry. The Company acquired the digital likeness rights of three late celebrities - Michael Jackson, Elvis Presley and Marilyn Monroe – and produced the Virtual Michael Jackson Show at the 2014 Billboard Music Awards. This performance was broadcast live to more than 11 million viewers and generated (estimate) more than 98 billion Internet impressions in the weeks that followed.

The Company is focusing initially on the entertainment and media marketplace, which is expected to generate $2.152 trillion in worldwide revenues by 2017. Pulse plans to produce digital media product that will penetrate every sector of this industry, and be consumed by global audiences on the growing variety of screens and stages available today – from theaters and television, tablets and phones, to stages and dynamic live performance venues around the world.

The Company's goal is to expand into life sciences, education and telecommunications and to become the world's leading developer and producer of digital human beings. Company leadership believes Pulse will accomplish this goal by owning, or materially participating in, the intellectual property rights of a substantial portfolio of human likenesses that produce high-margin, recurring revenues from a broad array of digital human applications around the world. The Company has recently launched a 75% owned subsidiary, Pulse Biologic, to pursue opportunities in surgical simulation, life sciences and medical applications.

Today, the applications for digital humans are obvious and in high demand in the entertainment sector. Tomorrow, digital humans will drive globally relevant - and highly lucrative – uses in surgical simulation, military simulation and telecommunications.
http://www.pulse.co

Contact:
Melissa Santiago
melissa.santiago(at)pulse.co
Pulse Evolution Corporation
(772) 345-4100

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12631087.htm

Pulse Evolution Corporation Media Relations Department +1 (772) 345-4100

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading